I messed up my poster so attaching slides here (Abstract 9529: A model comparing the value of broad next-gen sequencing (NGS)-based testing to single gene testing (SGT) in patients with nonsquamous non-small cell lung cancer (NSCLC) in the United States) #ASCO20 #LCSM 1/6

Although targeted treatments work well and we have 7 targets with FDA-approved drugs (EGFR/ALK/ROS1/BRAF/RET/MET/NTRK) testing levels are inadequate esp beyond EGFR/ALK, and many NSCLC who may benefit from tx pts die unidentified #ASCO20 #LCSM

We created a model using costs of testing just for EGFR/ALK vs broad NGS and potential testing levels of eligible pts in US, with potential LYG through IDing and treating pts #ASCO20 #LCSM

#ASCO20 #LCSM

Testing more pts with NGS results in many more pts with alterations being identified and treated, w increasing LYG. The converse is that not testing results in huge numbers of life-years lost. Testing and treating every potential pt in US very affordable #ASCO20 #LCSM

So the bottom line is that many many life years can be gained by testing all eligible NSCLC pts using broad NGS for targetable alterations and treating them, for a very manageable cost #ASCO20 #LCSM